Conditional Survival (CS) Analysis of Liver Resection (LR) for Gastro-Entero-Pancreatic Neuroendocrine Tumor (GEP-NET). Abstract #1927

Introduction: LR with curative intent in metastatic GEP-NET is rarely feasible associated with improved survival and symptoms control. CS is the probability that pts will survive an additional number of yrs given that they have already survived at a certain interval
Aim(s): There is no study on CS in pts undergoing GEP-NET LR
Materials and methods: 87 pts with GEP-NET liver mets underwent LR with curative intent (1995-2015). Cox proportional hazard regression model was applied to evaluate OS, TTR and associated prognostic factors. 3-year CS estimates at ‘t’ yrs after LR were calculated as: CS (t) = S (t + 3)/S (t)
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Surgeon Jorgelina Coppa

To read results and conclusion, please login ...

Further abstracts you may be interested in

#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment
Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
#1521 Metastatic Disease in Gastroenteropancreatic Neuroendocrine Cancer: Incidence, Treatment and Survival
Introduction: Data on patients with metastatic disease from GEP-NETs are rare.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ariana Madani
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
#1848 Liver Metastatic Disease (LMD) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Incidence, Treatment and Survival in a Multicenter Study in Argentina. Preliminary Report. ARGENTUM GROUP
Introduction: The first observational Study from our Group in Argentina, showed 60% incidence of liver mets at initial diagnosis. The treatment encompasses a wide scope of surgical and non-surgical modalities.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
Keywords: Liver, NETs